论文部分内容阅读
滤泡性淋巴瘤(follicular lymphoma,FL)是最常见的惰性非霍奇金淋巴瘤(non-Hodgkin’s lymphoma,NHL),其发病率逐年增高,但它是对放疗和化疗最敏感的恶性肿瘤之一。FL在不同发病阶段采取不同治疗方案:在早期阶段,主要为放射治疗;在疾病进展至中晚期时,进行联合化疗或免疫治疗。免疫治疗中,嵌合抗原受体(chimeric antigen receptor,CAR)修饰T细胞(CAR-T)是从基因层面研究出来的精准靶向治疗的新方法,组蛋白去乙酰化酶(histone deacetylase,HDAC)抑制剂与肿瘤细胞存活关系密切,使用肿瘤疫苗可增强FL的抗肿瘤免疫,免疫调节剂调节肿瘤生存的免疫微环境并同传统化疗药物起到协同作用,新型单克隆抗体的研究将突破原有单克隆抗体的局限性而发挥更好疗效。上述治疗研究仍处于临床试验阶段,需进一步研究发挥治疗作用。本文就FL免疫治疗方面的新进展,如使用CAR-T细胞、HDAC抑制剂、肿瘤疫苗、免疫调节剂和新型单克隆抗体等进行治疗作一综述。
Follicular lymphoma (FL) is the most common non-Hodgkin’s lymphoma (NHL). The incidence of this disease is increasing year by year, but it is the most sensitive malignant tumor to radiotherapy and chemotherapy one. FL at different stages of the disease to take a different treatment options: in the early stages, mainly for radiation therapy; advanced disease in the advanced stage, the combination of chemotherapy or immunotherapy. In immunotherapy, the chimeric antigen receptor (CAR) modified T cell (CAR-T) is a new method of precise targeted therapy developed from the gene level. Histone deacetylase (HDAC) ) Inhibitors are closely related to the survival of tumor cells. The use of tumor vaccines can enhance the anti-tumor immunity of FL. Immunomodulators can modulate the immune microenvironment of tumor survival and play a synergistic effect with traditional chemotherapy drugs. The research of new monoclonal antibodies will break through the original Monoclonal antibodies have the limitations and play a better effect. The above treatment research is still in the clinical trial stage, and needs further study to play a therapeutic role. This article reviews recent advances in FL immunotherapy, such as treatment with CAR-T cells, HDAC inhibitors, tumor vaccines, immunomodulators and novel monoclonal antibodies.